- Home
- WWR vs ICCC Comparison
WWR vs ICCC Comparison
Compare WWR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- ICCC
- Stock Information
- Founded
- WWR 1977
- ICCC 1982
- Country
- WWR United States
- ICCC United States
- Employees
- WWR N/A
- ICCC N/A
- Industry
- WWR Metal Mining
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- ICCC Health Care
- Exchange
- WWR Nasdaq
- ICCC Nasdaq
- Market Cap
- WWR 45.0M
- ICCC 39.2M
- IPO Year
- WWR N/A
- ICCC 1987
- Fundamental
- Price
- WWR $0.57
- ICCC $4.96
- Analyst Decision
- WWR Strong Buy
- ICCC
- Analyst Count
- WWR 1
- ICCC 0
- Target Price
- WWR $2.50
- ICCC N/A
- AVG Volume (30 Days)
- WWR 564.2K
- ICCC 13.6K
- Earning Date
- WWR 03-20-2025
- ICCC 05-13-2025
- Dividend Yield
- WWR N/A
- ICCC N/A
- EPS Growth
- WWR N/A
- ICCC N/A
- EPS
- WWR N/A
- ICCC N/A
- Revenue
- WWR N/A
- ICCC $26,493,000.00
- Revenue This Year
- WWR N/A
- ICCC N/A
- Revenue Next Year
- WWR N/A
- ICCC N/A
- P/E Ratio
- WWR N/A
- ICCC N/A
- Revenue Growth
- WWR N/A
- ICCC 51.63
- 52 Week Low
- WWR $0.40
- ICCC $3.34
- 52 Week High
- WWR $1.32
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- WWR 37.61
- ICCC 49.78
- Support Level
- WWR $0.55
- ICCC $4.56
- Resistance Level
- WWR $0.64
- ICCC $5.05
- Average True Range (ATR)
- WWR 0.05
- ICCC 0.27
- MACD
- WWR 0.00
- ICCC 0.01
- Stochastic Oscillator
- WWR 28.62
- ICCC 55.74
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.